In the wake of monoclonal antibodies within the asthma context (anti-IL5/5R, anti-IL-4/13R, anti-TSLP) [155,156,157,158], some of which directly affect airway remodeling or even inhibit mucus secretion, the implementation of “basic science” methods as a point-of-care or simply to guide therapy would be of great value (COPD CaRhe—clinicaltrial.gov, accessed on 21 December 2021, NCT04339270). This evidence concerns the gene IL5 and asthma.